Progression of liver fibrosis in HIV/hepatitis C virus-coinfected individuals on antiretroviral therapy with early stages of liver fibrosis at baseline

HIV Medicine

Volumn 15, Issue 4, 2014, Pages 203-212

  Sanmartin R ^a   Tor, J ^a   Sanvisens, A ^a   López, Jj ^a   Jou, A ^a   Muga, R ^a   Ojanguren, I ^a   Barluenga, E ^a   Videla, S ^a   Planas, R ^b   Clotet, B ^a   Tural, C ^a  

^a HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^b UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

Author keywords

HIV HCV coinfection; Liver biopsy; Liver fibrosis; Transient elastometry

Indexed keywords

CHOLESTEROL; HEPATITIS B SURFACE ANTIGEN; INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; TRIACYLGLYCEROL;

ADULT; ANTIRETROVIRAL THERAPY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CHILD PUGH SCORE; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; DISEASE COURSE; DISEASE SEVERITY; FATTY LIVER; FEMALE; FOLLOW UP; GENOTYPE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MIXED INFECTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCORING SYSTEM;

HIV/HCV COINFECTION; LIVER BIOPSY; LIVER FIBROSIS; TRANSIENT ELASTOMETRY;

ADULT; AGE FACTORS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; COINFECTION; DISEASE PROGRESSION; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INTERFERONS; LIVER CIRRHOSIS; MALE; PROSPECTIVE STUDIES; RETROSPECTIVE STUDIES; RIBAVIRIN; RISK FACTORS;

EID: 84895107886     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/hiv.12105     Document Type: Article

References (36)

1. Zeuzem S, Andreone P, Pol S etal. Telaprevir for retreatment of HCV infection. N Engl J Med 2011; 364: 2417-2428.
2. Sherman KE, Flamm SL, Afdhal NH etal. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365: 1014-1024.
3. Bacon BR, Gordon SC, Lawitz E etal. Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1207-1217.
4. Poordad F, McCone J Jr, Bacon BR etal. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 2011; 364: 1195-1206.
5. Fontaine H, Nalpas B, Poulet B etal. Hepatitis activity index is a key factor in determining the natural history of chronic hepatitis C. Hum Pathol 2001; 32: 904-909.
6. Saadeh S, Cammell G, Carey WD, Younossi Z, Barnes D, Easley K. The role of liver biopsy in chronic hepatitis C. Hepatology 2001; 33: 196-200.
7. Seeff LB. Natural history of chronic hepatitis C. Hepatology 2002; 36 (Suppl 1): S35-S46.
8. Ghany MG, Nelson DR, Strader DB, Thomas DL, Seeff LB. American Association for Study of Liver Diseases. An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology 2011; 54: 1433-1444.
9. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001; 344: 495-500.
10. Benhamou Y, Bochet M, Di Martino V etal. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. Hepatology 1999; 30: 1054-1058.
11. Fuster D, Planas R, Muga R etal. Advanced liver fibrosis in HIV/HCV-coinfected patients on antiretroviraltherapy. AIDS Res Hum Retroviruses 2004; 20: 1293-1297.
12. Mallolas J, Pol S, Rivero A etal. Boceprevir Plus Peginterferon/Ribavirin for the Treatment of HCV/HIV Co-Infected Patients: End of Treatment (Week 48) Interim Results. 47th Annual Meeting of the European Association for the Study of the Liver. Spain, Barcelona, 2012 [Abstract 366].
13. Sulkowski MS, Sherman KE, Soriano V etal. Telaprevir in Combination with Peginterferon Alfa-2a/Ribavirin in HCV/HIV Co-Infected Patients: SVR24 Final Study Results. 63rd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD 2012). Boston, MA, 2012 [Abstract 54].
14. Martínez SM, Crespo G, Navasa M, Forns X. Noninvasive assessment of liver fibrosis. Hepatology 2011; 53: 325-335.
15. Scheuer PJ. Classification of chronic hepatitis: a need for reassessment. J Hepatol 1991; 13: 372-374.
16. Sanmartin R, de Felipe E, Tor J etal. Effect of liver fibrosis on long-term mortality in HIV/hepatitis c virus-coinfected individuals who are evaluated to receive interferon therapies in the highly active antiretroviral therapy era. AIDS Res Hum Retroviruses 2012; 28: 1235-1243.
17. Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-2474.
18. Sandrin L, Fourquet B, Hasquenoph JM etal. Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol 2003; 29: 1705-1713.
19. Soriano V, Puoti M, Sulkowski M etal. Care of patients coinfected with HIV and hepatitis C virus: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007; 21: 1073-1089.
20. Alberti KG, Eckel RH, Grundy SM etal. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009; 120: 1640-1645.
21. Chen TY, Ding EL, Seage Iii GR, Kim AY. Meta-analysis: increased mortality associated with hepatitis C in HIV-infected persons is unrelated to HIV disease progression. Clin Infect Dis 2009; 49: 1605-1615.
22. Limketkai BN, Mehta SH, Sutcliffe CG etal. Relationship of liver disease stage and antiviral therapy with liver-related events and death in adults coinfected with HIV/HCV. JAMA 2012; 308: 370-378.
23. Merchante N, Girón-González JA, González-Serrano M etal. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 2006; 20: 49-57.
24. Pineda JA, Aguilar-Guisado M, Rivero A etal. Natural history of compensated hepatitis C virus-related cirrhosis in HIV-infected patients. Clin Infect Dis 2009; 49: 1274-1282.
25. Pineda JA, Romero-Gómez M, Díaz-García F etal. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompensated cirrhosis. Hepatology 2005; 41: 779-789.
26. Tural C, Fuster D, Tor J etal. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 2003; 10: 118-125.
27. Bräu N, Salvatore M, Ríos-Bedoya CF, Fernández-Carbia A, Paronetto F, Rodríguez-Orengo JF. Slower fibrosis progression in HIV/HCV-coinfected patients with successful HIV suppression using antiretroviral therapy. J Hepatol 2006; 44: 47-55.
28. Blanco F, Barreiro P, Ryan P etal. Risk factors for advanced liver fibrosis in HIV-infected individuals: role of antiretroviral drugs and insulin resistance. J Viral Hepat 2011; 18: 11-16.
29. Macías J, Berenguer J, Japón MA etal. Fast fibrosis progression between repeated liver biopsies in patients coinfected with human immunodeficiency virus/hepatitis C virus. Hepatology 2009; 50: 1056-1063.
30. Sulkowski MS, Mehta SH, Torbenson MS etal. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS 2007; 21: 2209-2216.
31. Sherman KE, Andersen JW, Butt AA etal. Sustained long-term antiviral maintenance therapy in HCV/HIV-coinfected patients (SLAM-C). J Acquir Immune Defic Syndr 2010; 55: 597-605.
32. Kanwal F, Hoang T, Kramer JR etal. Increasing prevalence of HCC and cirrhosis in patients with chronic hepatitis C virus infection. Gastroenterology 2011; 140: 1182-1188.
33. Davis GL, Albright JE, Cook SF, Rosenberg DM. Projecting future complications of chronic hepatitis C in the United States. Liver Transpl 2003; 9: 331-338.
34. Pineda JA, García-García JA, Aguilar-Guisado M etal. Clinical progression of hepatitis C virus-related chronic liver disease in human immunodeficiency virus-infected patients undergoing highly active antiretroviral therapy. Hepatology 2007; 46: 622-630.
35. Berenguer J, Alvarez-Pellicer J, Martín PM etal. Sustained virological response to interferon plus ribavirin reduces liver-related complications and mortality in patients coinfected with human immunodeficiency virus and hepatitis C virus. Hepatology 2009; 50: 407-413.
36. European AIDS Clincal Society (EACs) guidelines version 6.1. Treatment and recommendations for therapy of Hepatitis C in HIV coinfection. Available at: http://www.europeanaidsclinicalsociety.org (accessed 15 May 2013).